Monday, October 3, 2022


Biotechnology News Magazine

StemSpine Pilot Study Shows Positive Top-Line Results

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

StemSpine Pilot Study two-Year follow-up results confirm significant efficacy and no Serious adverse effects in patients using StemSpine procedure for treating chronic lower back pain.

Creative Medical Technology Holdings notes StemSpine® is a patented procedure that utilizes a patient’s own bone marrow aspirate for the treatment of chronic lower back pain.

There were no safety related concerns at up to two years and the StemSpine® procedure resulted in an efficacy rate of 87% in the treated patients. The Company plans to submit a manuscript for publication in a peer reviewed journal and present the data at future orthopedic/sports medicine conferences.

“The positive two-year data from our StemSpine pilot study are very encouraging, and we are excited to engage with practitioners on commercialization,” said Timothy Warbington, President and CEO of the Company.  “To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby repairing, remodeling and improving the blood supply around the disc and lower back area.  We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from non-surgical chronic lower back pain.”

Sahil Nock, Chief Commercialization Officer of the Company, added, “Given our timely receipt of this significant and favorable data, I look forward to accelerating our StemSpine® program by introduction to the physician community at the American Academy of Orthopaedic Surgeons annual conference taking place in Chicago this week, March 22-26. Building out strong advisory boards with notable KOLs has been a pillar of my career and I am excited to leverage my experience to accelerate our efforts to translate the StemSpine® procedure.”

The Company plans to hold a series of 1:1 meetings with physicians throughout the conference.  Please contact Sahil Nock utilizing information found at the end of this press release if you would like to connect.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine